Form 4: ProKidney Director Aaron Cowen Reports Ceasing 10% Beneficial Ownership Status

Aaron Cowen, a director of ProKidney Corp., has filed an exit Form 4 indicating he is no longer a beneficial owner of more than 10% of the company's Class A common stock, a change attributed to an increase in outstanding shares.

Summary

• Aaron Cowen, a director of ProKidney Corp. and associated with Suvretta Capital Management, LLC, has filed a Form 4.
• The filing is an 'exit' Form 4, voluntarily submitted to report that Cowen is no longer a beneficial owner of more than 10% of ProKidney Corp.'s outstanding Class A common stock.
• The change in 10% ownership status is based on the increased number of Class A common shares outstanding, as reported by ProKidney Corp. on July 3, 2025, in a Post-Effective Amendment No. 1 to its Registration Statement on Form S-3.
• The beneficial ownership information for Aaron Cowen has not changed from what was previously reported in his Form 3 filed on October 22, 2024, indicating no sale of shares by Cowen.

Sentiment

Score: 5

Explanation: The document is a factual, technical filing reporting a change in ownership status due to an increase in outstanding shares, not a sale. It carries a neutral sentiment.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategy.

Management Comments

• The beneficial ownership information of Aaron Cowen has not changed from information set forth in the Form 3 filed by the Reporting Person on October 22, 2024.
• This 'exit' Form 4 is voluntarily filed solely to report that the Reporting Person is no longer the beneficial owner of more than 10% of the outstanding shares Class A common stock, par value $0.0001 per share (the 'Class A common stock'), of ProKidney Corp. (the 'Issuer'), based on the number of shares of the Class A common stock outstanding as reported by the Issuer on July 3, 2025 in the Post-Effective Amendment No. 1 to the Registration Statement on Form S-3 filed on July 3, 2025 with the Securities and Exchange Commission.

Industry Context

This filing is a routine disclosure of a change in a director's beneficial ownership percentage, which is a common occurrence in publicly traded companies, especially following share issuances that dilute existing stakes. It does not provide broader industry context.

Stakeholder Impact

• Shareholders: The increase in outstanding shares, which led to the director no longer being a 10% owner, implies a dilution of existing shareholdings, though the specific impact depends on the purpose and terms of the share issuance.

Key Dates

Keywords

ProKidney Corp, PROK, Aaron Cowen, SEC Form 4, Beneficial Ownership, 10% Owner, Class A Common Stock, Suvretta Capital Management